Showing 137 news articles about Injectable & long-acting HIV treatment

Filters Content type: Editors' picks Topic: Injectable & long-acting HIV treatment

Research into injectable medications and other innovative forms of HIV treatment. It is hoped that they may only need to be taken every few weeks or months, rather than daily.

 

Injectable & long-acting HIV treatment

Long-Acting Injectables Are Effective for Homeless People

Editor's pick
POZ
10 July 2024
Adherence

Overcoming the Challenges of Adhering to Injectable ART and PrEP

Editor's pick
Infectious Disease Special Edition
26 June 2024
Access to healthcare

Celebrities join campaigners in call for cheaper version of ‘gamechanger’ HIV drug for poorer countries

Editor's pick
The Guardian
30 May 2024
Injectable & long-acting HIV treatment

U.S. Survey Reports Middling Interest in Long-Acting Injectable Treatment Among Women With HIV

Editor's pick
TheBodyPro
21 May 2024
Injectable & long-acting HIV treatment

US: Some State ADAP Programs Are Not Covering Long-Acting Injectable HIV Medications Like Cabenuva

Editor's pick
TheBody
13 May 2024
Injectable & long-acting HIV treatment

Just as CROI Gets Ready to Start, an Important Change to the IAS-USA HIV Treatment Guidelines

Editor's pick
HIV and ID Observations
3 March 2024
Injectable & long-acting HIV treatment

Top 10 HIV Clinical Developments of 2023

Editor's pick
TheBodyPro
1 December 2023
Injectable & long-acting HIV treatment

In-depth: How do long-acting HIV treatments work?

Editor's pick
Spotlight
14 November 2023
Access to healthcare

Patients, doctors, advocates launch campaign to press for increased use of injectable HIV medication in British Columbia

Editor's pick
CBC
8 November 2023
Injectable & long-acting HIV treatment

Cabotegravir/Rilpivirine Injections Administered During Home Health Visit Show Promise in Pilot Study

Editor's pick
TheBodyPro
26 October 2023
Injectable & long-acting HIV treatment

ViiV Healthcare receives approval from China’s national medical products administration for Vocabria (cabotegravir) used in combination with Rekambys (rilpivirine)

Editor's pick
ViiV press release
26 October 2023
People with limited treatment options

Intramuscular Administration of HIV Treatment Ibalizumab Compared With IV Infusion

Editor's pick
Monthly Prescribing Reference
17 October 2023
Injectable & long-acting HIV treatment

Over 80% With Detectable HIV Load Respond to CAB + RPV LA

Editor's pick
NATAP
17 October 2023
Injectable & long-acting HIV treatment

Treatment Adherence, Persistence in HIV Improves After Switch to Long-Acting ART

Editor's pick
Infectious Disease Advisor
17 October 2023
Pharmaceutical industry

People with HIV offered hope of self-injected drug at home

Editor's pick
The Guardian
3 October 2023
Injectable & long-acting HIV treatment

Could this new hydrogel make HIV therapy more convenient?

Editor's pick
EurekAlert!
28 September 2023
Treatment guidelines

Long-Acting Cabotegravir-Rilpivirine for People Not Taking Oral Therapy — Time to Modify Treatment Guidelines?

Editor's pick
HIV and ID Observations
25 September 2023
The search for a cure

Study demonstrates ability to remove key barrier to an HIV cure

Editor's pick
Medical Xpress
25 July 2023
Injectable & long-acting HIV treatment

The Yin and the Yang of Cabotegravir-Rilpivirine: Part One, the Good News

Editor's pick
HIV and ID Observations
4 July 2023
Injectable & long-acting HIV treatment

Going Long

Editor's pick
POZ
26 June 2023
Injectable & long-acting HIV treatment

Study of Weekly Oral HIV Treatment Resumes

Editor's pick
POZ
8 May 2023
Injectable & long-acting HIV treatment

Why is British Columbia gatekeeping injectable HIV medication?

Editor's pick
Xtra Magazine
4 April 2023
Injectable & long-acting HIV treatment

Clinic finds almost half of people who want long-acting HIV treatment don’t initiate it

Editor's pick
CATIE
30 March 2023
Injectable & long-acting HIV treatment

ViiV Healthcare announces positive data demonstrating long-acting injectable Cabenuva (cabotegravir, rilpivirine) is as effective as daily oral Biktarvy (BIC/FTC/TAF) for the treatment of HIV-1

Editor's pick
ViiV press release
23 February 2023